Henry Schein (NASDAQ:HSIC) Releases FY 2024 Earnings Guidance

Henry Schein (NASDAQ:HSIC) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 4.740-4.740 for the period, compared to the consensus estimate of 4.770. The company issued revenue guidance of $12.7 billion-$12.7 billion, compared to the consensus revenue estimate of $12.8 billion. Henry Schein also updated its Q4 2024 guidance to 1.190-1.190 EPS.

Henry Schein Stock Performance

Henry Schein stock opened at $80.03 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The stock has a fifty day moving average of $73.31 and a two-hundred day moving average of $71.34. The company has a market capitalization of $9.98 billion, a price-to-earnings ratio of 32.93, a PEG ratio of 2.20 and a beta of 0.89. Henry Schein has a fifty-two week low of $63.67 and a fifty-two week high of $82.63.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.05. The company had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm’s revenue for the quarter was up .4% compared to the same quarter last year. During the same period last year, the company earned $1.32 EPS. On average, analysts anticipate that Henry Schein will post 4.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on HSIC. Barrington Research increased their target price on Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday. Jefferies Financial Group raised their target price on shares of Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. Bank of America upgraded shares of Henry Schein from an “underperform” rating to a “buy” rating and lifted their price target for the company from $69.00 to $84.00 in a report on Monday, January 6th. Finally, Mizuho started coverage on Henry Schein in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $80.10.

Insider Activity at Henry Schein

In other Henry Schein news, COO Michael S. Ettinger sold 12,240 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the completion of the sale, the chief operating officer now owns 87,706 shares in the company, valued at $6,577,950. This trade represents a 12.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.14% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.